Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
RMD Open
|
November 2, 2022
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
Jeffrey I Weitz, Zoltán Szekanecz, Christina Charles-Schoeman, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 21, 2014
Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody
Chris B Russell, Hugh Rand, Jeannette Bigler, et al.
BMC Infectious Diseases
|
June 13, 2014
Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011
David A Martin, Paula M Luz, Jordan E Lake, et al.
Pharmaceutical Research
|
September 13, 2014
Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus
Ping Chen, Thuy Vu, Adimoolam Narayanan, et al.
Heart Rhythm
|
November 18, 2017
Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices
Carlos de Diego, Luis González-Torres, José María Núñez, et al.
Arthritis Research & Therapy
|
November 30, 2013
A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis
David A Martin, Melvin Churchill, Luis Flores-Suarez, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 17, 2023
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial
Philip Mease, Philip Helliwell, Paula Silwinska-Stanczyk, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
January 25, 2017
Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon-γ Antibody, in Patients With Discoid Lupus Erythematosus
Victoria P Werth, David Fiorentino, Barbara A Sullivan, et al.
Journal of Clinical Pharmacology
|
September 11, 2023
Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open-Label, Phase 1 Study
David A Martin, Jean-Baptiste Telliez, Susan Pleasic-Williams, et al.
Arthritis Research & Therapy
|
June 6, 2024
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis
Stanley Cohen, Jean S Beebe, Vishala Chindalore, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
RMD Open
|
November 2, 2022
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
Jeffrey I Weitz, Zoltán Szekanecz, Christina Charles-Schoeman, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 21, 2014
Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody
Chris B Russell, Hugh Rand, Jeannette Bigler, et al.
BMC Infectious Diseases
|
June 13, 2014
Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011
David A Martin, Paula M Luz, Jordan E Lake, et al.
Pharmaceutical Research
|
September 13, 2014
Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus
Ping Chen, Thuy Vu, Adimoolam Narayanan, et al.
Heart Rhythm
|
November 18, 2017
Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices
Carlos de Diego, Luis González-Torres, José María Núñez, et al.
Arthritis Research & Therapy
|
November 30, 2013
A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis
David A Martin, Melvin Churchill, Luis Flores-Suarez, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 17, 2023
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial
Philip Mease, Philip Helliwell, Paula Silwinska-Stanczyk, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
January 25, 2017
Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon-γ Antibody, in Patients With Discoid Lupus Erythematosus
Victoria P Werth, David Fiorentino, Barbara A Sullivan, et al.
Journal of Clinical Pharmacology
|
September 11, 2023
Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open-Label, Phase 1 Study
David A Martin, Jean-Baptiste Telliez, Susan Pleasic-Williams, et al.
Arthritis Research & Therapy
|
June 6, 2024
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis
Stanley Cohen, Jean S Beebe, Vishala Chindalore, et al.
Page
of 5